Artificial Hip Company Paying Massachusetts $1.35 Million to Settle Deception Case

A maker of artificial hips and knees agreed to a $1.35 million settlement with the Commonwealth of Massachusetts to resolve allegations that it marketed its products without regulatory approval and misled health care providers about their uses, The New York Times reports.

State Attorney General Martha Coakley said Stryker Corp.’s biotech unit violated Massachusetts’ Consumer Protection Act by engaging in unfair and deceptive practices to boost sales of bone-strengthening and bone-growth products.

The attorney general’s investigation examined the marketing of OP-1 implant and OP-1 putty, which were used to treat weakened bones. The products had limited approval by the U.S. Food and Drug Administration, and could be used to treat patients only if they had received approval from a hospital’s Institutional Review Board

Coakley said Stryker marketed its products beyond those limits, and misled health care professionals about the restrictions.

The company’s biotech unit, and former Stryker president Mark Philip, were indicted in October, 2009, for misleading the FDA about the use of the company’s products. The defendants have pleaded not guilty.

Stryker, which is based in Kalamazoo, Mich., did not admit any liability in the Massachusetts settlement, the Times reports.

Hip implants also have been a source of trouble recently at Johnson & Johnson. The company announced a recall of two kinds of hip replacements Thursday, two years after the FDA began receiving complaints about them.

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment